Global Ophthalmic Drugs Market Forecast 2017-2027

眼薬の世界市場

◆タイトル:Global Ophthalmic Drugs Market Forecast 2017-2027
◆商品コード:VGAIN7081168
◆調査・発行会社:visiongain
◆発行日:2017年6月
◆ページ数:306
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥387,345見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、眼薬の世界市場について調査・分析し、眼薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・眼薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・眼薬の世界市場:セグメント別市場分析
・眼薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

The global ophthalmic drugs market is expected to grow at a CAGR of 4.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.6% from 2017-2027. The market is estimated at $23bn in 2016 and $28.1bn in 2021. In 2016, the retinal disorder drugs submarket held 40% of the share in this market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 306-page report you will receive 125 tables and 113 figures – all unavailable elsewhere.

The 306-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Ophthalmic Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecasts to 2027 for the global ophthalmic drugs market by the leading submarkets:
- Retinal Disorder Drugs
- Allergic, Inflammatory & Infective Drugs
- Glaucoma Drugs
- Dry Eye Drugs
- Other Ophthalmic Drugs

• This report includes revenue forecasts to 2027 for the following ophthalmic drugs:
- Eylea
- Lucentis
- Avastin
- Visudyne
- Jetrea
- Pataday
- Vigamox
- Patanol
- TobraDex
- Cravit
- AzaSite
- Acular
- Lumigan and Ganfort
- Xalatan/Xalacom
- Travatan/Travatan Z and DuoTrav
- Alphagan/Alphagan P and Combigan
- Azopt
- Trusopt
- Zioptan
- Cosopt
- Tapros/Taflotan
- Restasis
- Refresh
- Hyalein
- Diquas

• This report provides individual revenue forecasts to 2027 for these national markets:
- The US
- Japan
- EU5: Germany, France, the UK, Spain, Italy
- Russia
- China
- India
- Brazil
- Rest of the World

• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market

• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
- Novartis
- Regeneron
- Allergan
- Roche
- Valeant
- Santen
- Bayer
- Pfizer
- Senju

Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

【レポートの目次】

1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate and Functionally Intricate Organs
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause of Vision Loss
2.5.1 A Classification of Glaucoma
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Risk factor of Diabetic Retinopathy
2.7.3 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Risk factors of Ocular Inflammatory Disease
2.9.2 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition in This Report

3. The Global Ophthalmic Drugs Market, 2017-2027
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation of the Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2016
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2017-2027
3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2017-2027

4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2016-2027
4.1 Leading Products in the Retinal Disorder Drugs Market, 2016
4.2 Retinal Disorders: Market Trends and Developments, 2016
4.2.1 The Rise and Rise of Eylea
4.2.2 The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
4.2.5 Drug/Device Combination Products Entering the Market
4.2.6 Does Regenerative Medicine Have a Successful Future in Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2017-2027
4.3.1 Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2017-2027
4.4 Leading Drugs for The Treatment of Retinal Disorders
4.5 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.5.1 Recent Approvals for Eylea
4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.5.3 Eylea: Sales Forecast 2016-2027
4.5.4 Possible Combination Therapies Involving Eylea
4.6 Lucentis (ranibizumab) – Roche/ Novartis
4.6.1 Lucentis: Sales Forecast 2016-2027
4.6.2 Less Frequent Dosing Approved in US for Lucentis
4.6.3 New Indications for Lucentis
4.6.4 Possible Combination Therapy Involving Lucentis
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2017-2027
4.7.2 Compounding Pharmacies and Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2016-2027
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans for Jetrea
4.9.3 Jetrea: Sales Forecast 2016-2027
4.9.4 Possible Acquisition Move on ThromboGenics
4.9.5 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2016-2027

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2016-2027
5.1 Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2016
5.2 Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2016
5.2.1 The Growth Prospects for Allergic, Inflammatory and Infective Drugs
5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
5.3 Allergic, Inflammatory and Infective Drugs: Market Forecast 2016-2027
5.3.1 Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2017-2027
5.4 Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions
5.5 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.5.1 Pataday: Sales Forecast 2016-2027
5.5.2 Impending Generic Competition for Patanol And Pataday
5.5.3 Approval of Pazeo Solution
5.5.4 Patanol: Sales Forecast 2016-2027
5.6 Vigamox (moxifloxacin) – Alcon (Novartis)
5.6.1 Intensifying Competition and Generics Drug Challenge to Vigamox
5.6.2 Moxeza: A Next-Generation Form of Vigamox
5.6.3 Vigamox: Sales Forecast 2016-2027
5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.7.1 The Development and Commercialisation of TobraDex ST
5.7.2 TobraDex: Sales Forecast 2016-2027
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2016-2027
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2016-2027
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2016-2027
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2016-2027

6. Glaucoma Drugs Market: Market Analysis and Forecast 2016-2027
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products in The Glaucoma Drugs Market, 2016
6.2 Glaucoma Drugs: Market Trends and Developments, 2017
6.2.1 Patent Expiration: A Major Restraint for Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation in Treatments for Glaucoma
6.3 Simbrinza: First Beta-Blocker-Free Combination
6.4 Glaucoma Drugs: Market Forecast 2016-2027
6.4.1 Glaucoma Drugs: Changing Market Shares by Leading Drugs 2016-2027
6.5 Leading Drugs for The Treatment of Glaucoma
6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.6.1 Lumigan And Ganfort: Sales Forecast 2017-2027
6.7 Xalatan And Xalacom (latanoprost) – Pfizer
6.7.1 Xalatan/Xalacom: Sales Forecast 2017-2027
6.8 Travatan/Travatan Z and DuoTrav (travoprost) – Novartis
6.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2027
6.9 Alphagan/Alphagan P and Combigan (brimonidine) – Allergan
6.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2027
6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.10.1 Divestment Agreement with Santen And Akorn
6.10.2 Trusopt: Sales Forecast 2017-2027
6.10.3 Cosopt And Cosopt PF: Sales Forecast 2017-2027
6.11 Azopt (brinzolamide) – Novartis
6.11.1 Azopt: Sales Forecast 2017-2027
6.12 Tapros (tafluprost) – Santen
6.12.1 Tapros: Sales Forecast 2016-2027
6.13 Zioptan (tafluprost) – Akorn
6.13.1 Zioptan: Sales Forecast 2016-2027
6.14 Other Glaucoma Drugs: Sales Forecast 2017-2027

7. Dry Eye Drugs Market: Market Analysis and Forecast 2016-2027
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products in The Dry Eye Drugs Market, 2016
7.2 Dry Eye Drugs: Market Trends and Developments, 2016
7.2.1 Restasis: Patent Elongations and Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused on Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2017-2027
7.3.1 Dry Eye Drugs: Changing Market Shares by Leading Drugs 2017-2027
7.4 Leading Drugs for The Treatment of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis – Generic launch in 2016?
7.5.2 Restasis: Sales Forecast 2017-2027
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2017-2027
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2017-2027
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2017-2027
7.9 Other Dry Eye Drugs: Sales Forecast 2017-2027
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.2 Hetlioz: Sales Forecast 2017-2027

8. Leading National Markets for Ophthalmic Drugs, 2017-2027
8.1 The Ophthalmic Drugs Market by Region
8.1.1 The Global Distribution of Ophthalmic Drugs In 2016
8.2 Leading National Markets: Forecast 2017-2027
8.2.1 Changing Market Shares by Region, 2017-2027
8.3 Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2017-2027
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2017-2027
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2016-2027
8.5.2 Germany
8.5.3 France
8.5.4 UK
8.5.5 Italy
8.5.6 Spain
8.6 Japan
8.6.1 The Cost of Treatment in Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2017-2027
8.7 China
8.7.1 Expansion of Healthcare Coverage and Reimbursement in China
8.7.2 Price Controls and The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2016-2027
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2017-2027
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2016-2027
8.10 India
8.10.1 The Impact of The Drug Prices Control Order on Indian Pharma
8.10.2 India’s Expansion of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2017-2027
8.11 Rest of the World
8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2017-2027

9. Leading Companies in the Ophthalmic Drugs Market, 2017-2027
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.2 Leading Companies in The Ophthalmic Drugs Market, 2016
9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2017-2027
9.2.2 Ophthalmic Drugs: Changing Market Shares by Leading Companies 2017-2027
9.3 Novartis (Alcon)
9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2016
9.3.2 Novartis: Sales Forecast 2016-2027
9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016
9.3.4 Novartis: Recent Developments
9.4 Regeneron
9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2016
9.4.2 Regeneron: Recent Developments
9.4.3 Regeneron: Sales Forecast 2017-2027
9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2016
9.5 Allergan (Actavis)
9.5.1 Allergan: Ophthalmic Drugs Portfolio
9.5.2 Allergan: Recent Developments
9.5.3 New acquisitions for healthcare development
9.5.4 Allergan: Sales Forecast 2017-2027
9.5.5 Allergan: Ophthalmic Drugs Development Pipeline, 2016
9.6 Roche
9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016
9.6.2 Roche: Sales Forecast 2017-2027
9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2016
9.7.2 Valeant: Recent Developments
9.7.3 Valeant: Sales Forecast 2017-2027
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016
9.7.5 Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future
9.8 Santen
9.8.1 Santen: Ophthalmic Drugs Portfolio, 2016
9.8.2 Santen: Recent Developments
9.8.3 Santen: Sales Forecast 2017-2027
9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2017-2027

9.10 Pfizer
9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2017
9.10.2 Pfizer: Recent Developments
9.10.3 Pfizer: Sales Forecast 2017-2027
9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2017
9.11 Senju
9.11.1 Senju: Ophthalmic Drugs Portfolio
9.11.2 Senju: Sales Forecast 2017-2027
9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016

10. Ophthalmic Drugs: Research and Development Pipeline, 2017-2027
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders
10.2 Drugs for Retinal Disorders: Development Pipeline, 2016
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 CompaqSipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.3.2 Lipidil (fenofibrate) - Abbott
10.3.3 Iluvien (fluocinolone) – AlimeraSciences
10.4 Drugs in Phase 3 Development For Retinal Disorders
10.4.1 AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan
10.4.2 Fovista and Zimura – Ophthotech Corporation
10.4.3 Lampalizumab (anti-FactorD Fab) - Roche
10.4.4 MC-1101 (hydralazine) – Macu CLEAR
10.4.5 Squalamine (anti-angiogenic drug) - OHRPharmaceutical
10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.4.7 UF-021 (unoprostone) - R-TechUeno
10.5 Drugs in Phase 2 Development for Retinal Disorders
10.5.1 AKB-9778 (Tie2 activator) - AerpioTherapeutics
10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
10.5.3 AGN208397 (beclomethasone) - Allergan
10.5.4 CPC 551 - ColbyPharmaceutical
10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
10.5.7 LFG316 (anti-C5 mAb) - Novartis
10.5.8 Intravitreal brimonidine implant - Allergan
10.5.9 Optina (danazol) - AmpioPharmaceuticals
10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer
10.5.11 Premiplex (SHP-607) - Shire
10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech
10.5.13 Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA
10.6 DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders
10.6.1 BDM-E - BioDiem
10.6.2 NADPHOxidaseInhibitors – AlimeraSciences
10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica
10.6.4 PlasmaKallikreinInhibitors (KVD001) - KalVista
10.6.5 QLT091001 (synthetic retinoid) – QLT
10.7 Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.7.1 EGP-437 (dexamethasone) – EyeGatePharmaceuticals
10.7.2 IBI-10090 and IBI-20089 - IconBioscience
10.7.3 KPI-121 (loteprednol etabonate) - Kala
10.8 Drugs in Phase 2 Development for Allergic, Inflammatory And Infective Ophthalmic Conditions
10.8.1 CF101 (adenosine A3 receptor agonist) - Can-FiteBioPharma and OphthaliX
10.8.2 FST-100 (povidone-iodine/dexamethasone) - Shire
10.8.3 NVC-422 (auriclosene) - NovaBay
10.8.4 Sarilumab - Regeneron
10.9 Drugs in Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.9.1 Finafloxacin - MerLionPharmaceuticals/Novartis
10.10 Drugs for Glaucoma: Development Pipeline, 2016
10.11 Drugs in Phase 2&3 Development for Glaucoma
10.11.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
10.11.2 AMA0076 (ROCK inhibitor) - Amakem
10.11.3 Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.12 Drugs in Phase 1 And Pre-clinical Development For Glaucoma
10.13 Drugs in Phase 3 Development for Dry Eye
10.13.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.13.2 Lifitegrast (integrin antagonist) - Shire
10.13.3 Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan
10.13.4 SI-614 (modified hyaluronate) - Seikagaku
10.14 Drugs in Phase 2 Development for Dry Eye
10.14.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
10.14.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
10.15 Other Drugs in the Development Pipeline for Ophthalmic Conditions
10.15.1 Brimonidine For Eye Whitening - Valeant
10.15.2 GS-101 (aganirsen) - GeneSignal
10.15.3 Omidria (phenylephrine/ketorolac) – Omeros

11. Qualitative Analysis of the Ophthalmic Drugs Market, 2017-2027
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2027
11.3 Strengths
11.3.1 A Healthy R&D Pipeline
11.3.2 Advances in Drug Delivery Technologies
11.3.3 Support for Reimbursement and Payment Approvals
11.3.4 Gene Therapy and RNAi Technology
11.3.5 New Ophthalmic Therapeutic Applications for Drugs
11.3.6 Development of Neuroprotective Anti-Glaucoma Medications
11.3.7 Biomarkers as Tools for Better Diagnosis and Treatment
11.4 Weaknesses
11.4.1 Low Levels of Patient Adherence to Treatment
11.4.2 High Treatment Burden on Patients And Healthcare Providers
11.4.3 Under-Diagnosis and Under-Treatment
11.5 Opportunities
11.5.1 Sustained-Release Ocular Implants
11.5.2 The Impact of a Rapidly Ageing Global Population
11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
11.5.4 Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence
11.5.5 Unmet Clinical Need in Many Disease Areas
11.5.6 Economic Growth in Emerging Market Provide Opportunity for Expansion
11.6 Threats
11.6.1 Intensifying Price Regulation in The Market
11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands
11.6.3 Rising Cost Of R&D
11.6.4 Biosimilars – A Bigger Threat than Generics?
11.7 Porter’s Five Force Analysis of The Global Ophthalmic Drugs Market, 2017-2027
11.7.1 Threat of New Entrants
11.7.2 Rivalry Among Competitors
11.7.3 Power of Suppliers
11.7.4 Threat of Substitutes
11.7.5 Power of Buyers

12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2016-2027
12.2 Leading Sectors in Ophthalmic Drugs In 2016
12.3 Leading Regions in The Ophthalmic Drugs Market In 2016
12.4 Leading Companies in The Ophthalmic Drugs Market, 2016
12.5 What Does the Future Hold for Ophthalmic Drugs?

13. Glossary

Associated Report
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2016-2027 (Redacted Data)
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Main Classes of the Glaucoma Drugs, 2016
Table 2.3 Drug Treatments for Age-Related Macular Degeneration, 2017
Table 2.4 Drug Treatments for Ocular Allergy, 2016
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017
Table 2.6 Drug Treatments for Eye Infections, 2017
Table 2.7 Clinical Trial Phases, 2016
Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2016
Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2016-2027
Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2016-2021, 2021-2027, 2017-2027
Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2016, 2021, 2027
Table 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2016
Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR(%), 2016-2027
Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2016
Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2016
Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2016
Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2016-2027
Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2016
Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2016-2027
Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2016-2021, 2021-2027, and 2017-2027
Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2016, 2021, and 2027
Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.7 The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2016-2027
Table 8.8 The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2016
Table 8.9 The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.10 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2016, 2021, 2027
Table 8.11 The German Ophthalmic Drugs Market F orecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2027
Table 8.12 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2027
Table 8.13 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.14 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2027
Table 8.15 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.16 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.17 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.18 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.19 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.21 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2027
Table 8.22 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.23 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.24 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.25 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.26 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.27 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.28 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 8.29 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.30 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2027
Table 8.31 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.32 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027

Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2016
Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2016-2027
Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2016, 2021, 2027
Table 9.4 Novartis: Company Overview, 2016
Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
Table 9.6 Regeneron: Company Overview, 2016
Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.8 Allergan: Company Overview, 2016
Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.10 Roche: Company Overview, 2016
Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.13 Valeant: Company Overview, 2016
Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.15 Santen: Company Overview, 2016
Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.17 Bayer: Company Overview, 2016
Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.19 Pfizer: Company Overview, 2016
Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.21 Senju: Company Overview, 2016
Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 10.1 RetinalDisordersDrugsPipeline: Phase 3 Drugs, 2016
Table 10.2 RetinalDisordersDrugsPipeline: Phase 2 Drugs, 2016
Table10.2 RetinalDisordersDrugsPipeline: Phase 2 Drugs, 2016 (continued)
Table 10.3 RetinalDisordersDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016
Table 10.4 Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 3 Drugs, 2016
Table 10.5 Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 2Drugs, 2016
Table 10.6 Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016
Table 10.7 GlaucomaDrugsPipeline: Phase 2&3 Drugs, 2016
Table 10.8 GlaucomaDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016
Table 10.9 DryEyeDrugsPipeline: Phase 3 Drugs, 2016
Table 10.10 DryEyeDrugsPipeline: Phase 2 Drugs, 2016
Table 10.11 OtherPipelineProducts for OphthalmicConditions, 2016
Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2027
Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2016-2027
Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases
Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2016, 2021, 2027
Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2016, 2021, 2027

List of Figures
Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2017
Figure 2.1 Structure of The Human Eye
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2014
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.4 Classification of Glaucoma, 2016
Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2016
Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2016-2021
Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2021-2027
Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2017-2027
Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2016
Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2021
Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2027
Figure 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m), 2016
Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2016-2027
Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2016-2027
Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2016-2027
Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2016-2027
Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2016-2027
Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2016-2027
Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2016-2027
Figure 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2016
Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 5. 3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2016-2027
Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2016-2027
Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2016-2027
Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2016-2027
Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2016-2027
Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2016-2027
Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2016-2027
Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2016-2027
Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2016-2027
Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2016
Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2016-2027
Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2016-2027
Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2016-2027
Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2016-2027
Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2016-2027
Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2016-2027
Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2016-2027
Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2016-2027
Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2016-2027
Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2016-2027
Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2016-2027
Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2016
Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2016-2027
Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2016
Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2021
Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2027
Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2016-2027
Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2016-2027
Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2016-2027
Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2016-2027
Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2016-2027
Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2016
Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2016-2027
Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2016-2027
Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2016-2021
Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2021-2027
Figure 8.6 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2017-2027
Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2016
Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2021
Figure 8.9 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2027
Figure 8.10 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.11 The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2016
Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2016-2027
Figure 8.13 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2016
Figure 8.14 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2021
Figure 8.15 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2027
Figure 8.16 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.18 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.19 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
Figure 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
Figure 8.21 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
Figure 8.22 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
Figure 8.23 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.24 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
Figure 8.25 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.26 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2016
Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m) by Leading Companies, 2016-2027
Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2016
Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2021
Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2027
Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2016-2027
Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
Figure 11.3 Porter’s Five Force Analysis of the Ophthalmic Drugs Market, 2016
Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2016, 2021, 2027
Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2016-2027

【レポートのキーワード】

眼薬

★調査レポート[眼薬の世界市場] ( Global Ophthalmic Drugs Market Forecast 2017-2027 / VGAIN7081168) 販売に関する免責事項
[眼薬の世界市場] ( Global Ophthalmic Drugs Market Forecast 2017-2027 / VGAIN7081168) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆